Abstract | BACKGROUND: METHODS: Adopting 2007 ASCO/CAP guideline recommendations for HER2 testing, 27 tissue microarray (TMA) samples from EOC patients were analyzed by immunohistochemistry (IHC) using Dako, c-erb-B2 antibody and subsequently examined by fluorescence in situ hybridization (FISH) using Abbott/Vysis, PathVysion HER2 DNA Probe Kit. RESULTS: The overall concordance revealed 81.5% between HER2 IHC and HER2 FISH results. Additionally, HER2 gene copies prior to chromosome-17 correction increased significantly in a stepwise order through the negative, equivocal, and positive IHC result categories (P = 0.026), as did the HER2 gene copies after chromosome-17 correction (P = 0.028). On the other hand, HER2 IHC results correlated significantly with both chromosome-17 uncorrected HER2 gene copy numbers (ρ = 0.430, P = 0.025) and chromosome-17 corrected HER2 gene copy numbers (ρ = 0.524, P = 0.027). CONCLUSION: We demonstrated that both chromosome-17 corrected and uncorrected HER2 gene copies correlated significantly with HER2 IHC result categories; and tests for the HER2 gene copies per tumor cell either before or after correction for chromosome-17 can be applied as a potentially valuable tool in analyzing the HER2 status in EOC.
|
Authors | Wen-Chih Tsai, Ming-Yung Lee, Fong-Lin Chen, Po-Hui Wang, Wea-Lung Lin, Alexandra Ruan, Yi-Ju Li, Shao-Chuan Wang, Hung Chiang, Chih-Ping Han |
Journal | Archives of gynecology and obstetrics
(Arch Gynecol Obstet)
Vol. 284
Issue 3
Pg. 721-9
(Sep 2011)
ISSN: 1432-0711 [Electronic] Germany |
PMID | 21046136
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- ERBB2 protein, human
- Receptor, ErbB-2
|
Topics |
- Chromosomes, Human, Pair 17
(genetics)
- Female
- Gene Amplification
- Gene Dosage
- Genes, erbB-2
- Humans
- Immunohistochemistry
- In Situ Hybridization, Fluorescence
- Microarray Analysis
- Ovarian Neoplasms
(genetics, metabolism)
- Receptor, ErbB-2
(genetics, metabolism)
- Statistics, Nonparametric
|